Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Full Steam Ahead

<< Previous

Bullboard Posts

Next >>

Comment by Rosmorducon Apr 28, 2020 12:43pm

178 Views

Post# 30962447

RE:Full Steam Ahead

Yup.

We're consolidating here forming a very nice technical cup handle which is bullish.

The stock price (how it's trading) along with technicals and volume always tells you the story. If you have done your proper DD on top of that, you are solid.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success